1.
Gong W, Yu J, Zheng T, et al. CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease. Clin Transl Med. 2021;11(2):e339.
In this article, we realised an incorrect staining image was used in the Control group in Figure 6B, and an incorrect immunofluorescence image was used for ZO‐1 staining in the DSS+Piceatannol group in Figure 7C after a careful reexamination of the manuscript. Upon reviewing the original data, we realised that the mistake was made inadvertently during manuscript preparation. We have now replaced the correct images of Figures 6 and 7, while the description of Figures 6 and 7 in the results section of the original version does not need to be changed. We confirm that the errors did not affect the results, interpretation and conclusion of the study.
FIGURE 7.
FIGURE 6.
P‐NPs‐C alleviated intestinal inflammation during colitis. (A) Mucosal inflammation analyzed by histopathology was displayed (n = 610/group). Scale bars = 100 µm. (B) Cellular fractions of CD45+ leukocyte, CD3+ T cells, F4/80+ macrophages, and MPO+ neutrophils in colonic mucosa of DSS‐treated mice that were orally administered with P‐B;NPs‐C or piceatannol were determined by immunohistochemistry staining. Representative images were displayed. Scale bars + 100 µm. (C) The mRNA expressions of various inflammatory genes were quantified by real‐time PCR. Data were shown as mean values ± SD. *P < 0.05, **P < 0.01, and ns, no significance.
We apologise for this error.